

Automated Extraction of Catecholamines and Metanephrines from Human Plasma using Biotage® Extrahera™ LV-200 and Microelution SPE Prior to UHPLC-MS/MS Analysis




Figure 1. Structures of norepinephrine, epinephrine, dopamine, normetanephrine, metanephrine, and 3-methoxytyramine.

Introduction

This application note describes the extraction of six catecholamines and metanephrines from human plasma using Biotage® Mikro WCX SPE microelution plates prior to UHPLC-MS/MS analysis.

Our sample preparation procedure, using weak cation exchange mixed-mode solid phase extraction, delivers high recovery and consistent matrix factors whilst providing low limits of quantitation for all analytes.

The selection of plasma anticoagulant can have a significant effect on analyte stability and matrix interferences. The robust procedure in this application note has similar extraction characteristics for human plasma treated with commonly used anticoagulants.

The use of Biotage® Mikro SPE plates for extraction allows for low elution volumes and enhanced workflow efficiency.

This application note includes optimized conditions for automated processing of the Mikro plates (using Biotage® Extrahera LV-200, see appendix for settings) and manual processing (using the Biotage® PRESSURE+ 96 positive pressure manifold). Data generated using both processing systems is shown.

Analytes

Norepinephrine (NE), epinephrine (EP), dopamine (DA), normetanephrine (NE), metanephrine (ME), and 3-Methoxytyramine (3MT).

Internal Standards

Norepinephrine-D₆ (NE-D₆), epinephrine-D₆ (EP-D₆), dopamine-D₄ (DA-D₄), normetanephrine-D₃ (NE-D₃), and metanephrine-D₃ (ME-D₃). ME-D₃ was used as an internal standard for 3-MT.

Sample Preparation Procedure

Format

Biotage® Mikro WCX Plate, 2 mg, p/n 602-0002-LVP.

Sample Pre-Treatment

Centrifuge plasma samples for 10 min at 6,000 x g before processing further. Add 4 µL of working internal standard and 4 µL working standard diluent or working standard solution to 100 µL plasma. Vortex mix using a medium setting for 5 to 10 s. Pretreat spiked plasma with 100 µL 10 mM sodium citrate pH 7 and vortex mix using a medium setting for 5 to 10 s.

Automated And Manual Processing Conditions

Detailed automated processing conditions using the Biotage® Extrahera™ LV-200 system are included in the appendix.

Plates were processed manually using a Biotage® PRESSURE+ 96 positive pressure manifold. Each step described below was processed at 3 to 8 psi using the adjustable flow setting. Drying steps were processed at 40 psi using the maximum flow setting.

Condition

Add methanol (100 µL) to each well.

Equilibration

Add 10 mM ammonium acetate pH 6 (100 µL) to each well.

Sample Loading

Add pre-treated plasma (200 µL) to each well.

Wash 1

Add 10 mM ammonium acetate pH 6 (100 µL) to each well to elute aqueous interferences.

Wash 2

Add MeOH:H₂O (80:20, v/v, 100 µL) to each well to elute neutral organic interferences. On completion, dry the bed for 1 minute.

Wash 3

Add dichloromethane (100 µL) to each well to elute lipophilic interferences. On completion, dry the bed for 5 minutes.

Elution

Elute analytes with 100 µL of water: propan-2-ol (85:15, v/v) containing formic acid (0.1% v/v) into a 1 mL collection plate (p/n 121-5202). On completion, purge the bed at 12 psi (adjustable flow setting) for 5 seconds.

Post Elution And Reconstitution

Dry the extract in a stream of air or nitrogen using a Biotage® SPE Dry 96 at 40 °C using a flow rate of 40 to 60 L min⁻¹ (drying time under these conditions is approximately 20 mins).

Reconstitute evaporated samples with H₂O:MeOH (95:5, v/v, 100 µL) containing formic acid (0.1% v/v) and mix thoroughly. Cover with a sealing mat, vortex mix and transfer to LC vials containing 200 to 300 µL glass inserts, close with an appropriate cap (e.g. LC vials: Supelco p/n 854974; Snap Caps: Supelco p/n SU860093; Inserts: Agilent p/n 5183-2085).

UHPLC Parameters

Instrument

Shimadzu Nexera UHPLC

Column

Avantor® ACE Excel 1.7 C18-PFP (100 mm x 3.0 mm) column (p/n EXL-1710-1003U), with a RESTEK Raptor ARC-18 2.7 µM (5 mm x 2.1 mm) guard cartridge (p/n 9314A0252).

Mobile Phase

A: 2 mM ammonium formate containing formic acid (0.05% v/v) in water.

B: 0.5 mM ammonium fluoride in methanol.

Flow Rate

0.5 mL min⁻¹

Column Temperature

30 °C

Autosampler Temperature

10 °C

Injection Volume

10 µL

Table 1. UHPLC Gradient.

Time, min	% A	% B	Divert Valve
0.0	98	2	
0.5	98	2	to MS
3.0	70	30	
3.5	5	95	to waste
5.5	5	95	
6.0	98	2	
9.0	98	2	

MS Parameters

Instrument

AB SCIEX Triple Quad 5500 using a Turbo-V source and TurbolonSpray probe in positive ESI mode

IS Voltage (IS)

2500 V

Source Temperature (TEM)

500 °C

Curtain Gas (CUR)

35 psi

Nebulizer Gas (GS1)

50 psi

Heater Gas (GS2)

60 psi

CAD Gas

7

Data Acquisition

Scheduled MRM data acquisition, target scan time 0.40 s, detection window 60 s

Table 2. MRM Parameters.

Analyte	Transition, DA	DP, V	EP, V	CE, V	CXP, V
NE 1	152.1 > 106.9	35.0	5.0	23.5	16.5
NE 2	170.1 > 151.9	42.0	8.0	7.6	19.9
NE-D6	158.1 > 110.9	59.0	4.2	24.6	16.2
EP 1	166.1 > 106.8	102.0	12.0	25.5	13.4
EP 2	184.1 > 165.9	90.0	12.0	15.1	13.4
EP-D6	190.0 > 172.1	90.0	12.0	15.0	17.0
DA 1	154.1 > 90.8	60.0	10.0	31.4	11.3
DA 2	154.1 > 137.1	60.0	10.0	14.5	20.8
DA-D4	141.3 > 94.9	155.0	11.0	26.7	14.8
NM 1	166.1 > 133.9	55.5	3.2	22.0	16.0
NM 2	166.1 > 106.0	55.5	3.2	22.0	16.0
NM-D3	169.1 > 137.1	57.0	12.3	21.8	16.2
ME 1	198.1 > 180.1	56.2	11.0	23.0	17.0
ME 2	180.1 > 119.1	81.6	10.0	24.4	16.0
ME-D3	183.1 > 121.1	81.6	12.0	25.0	14.0
3MT 1	168.2 > 90.9	36.0	11.5	31.5	11.9
3 MT 2	151.2 > 119.0	88.0	11.5	19.3	13.8

Results

Recovery

Extraction recovery was determined using a 60 pg spike in 100 µL sodium citrate plasma. Data are the average of n=7 pre-extraction spikes compared to n=4 post extraction spikes (Figure 2). Recovery was determined for both the analyte and its associated internal standard. Data are tabulated for PRESSURE+ 96 and Extrahera™ LV-200 methods (table 3).




Figure 2. Recovery of catecholamines and metanephrines using the conditions described in this application note. Data is shown for each method (PRESSURE+ 96 and Extrahera™ LV-200).

Table 3. Extraction Recovery and Precision for Pooled Gender Human Plasma with Sodium Citrate Anticoagulant.

Method	Analyte	Recovery, %	Precision, % RSD
PRESSURE+ 96	NE	72	11.8
	EP	81	6.5
	DA	89	2.8
	NM	93	5.6
	ME	89	3.4
	3MT	93	2.8
Extrahera™ LV-200	NE	73	6.7
	EP	78	4.2
	DA	84	6.0
	NM	90	1.3
	ME	85	4.1
	3MT	90	6.4

Linearity And Limit Of Quantitation (LOQ)

Extracted analyte linearity was determined using stripped plasma prepared with an in-house procedure, serially diluted in matrix from 500 to 10 pg mL⁻¹ with internal standards at 200 pg mL⁻¹. Calibration range was determined where the calibration coefficient $r > 0.9975$ ($r^2 > 0.995$). The acceptance criteria used were: accuracy from 90 to 110% (lowest calibrant 80–120%); and precision < 10% RSD (lowest calibrant < 15%). LOQ determined where signal/noise was > 10:1, estimated.

Example calibration curves are demonstrated in Figure 3. Extracted ion chromatograms from potassium EDTA plasma spiked at 80 pg mL⁻¹ overlaid with the stripped blank are demonstrated in Figure 4. Method performance data are tabulated for two matrices using each method (Tables 4 and 5).




Figure 3. Extracted Matrix Calibration Curves (plasma with potassium EDTA anticoagulant) 10 to 500 pg mL⁻¹ (IS 200 pg mL⁻¹).




Figure 4. Extracted Ion Chromatograms, (80 pg mL⁻¹ spiked potassium EDTA plasma, overlaid with stripped blank).

Table 4. PRESSURE+ 96 Calibration Performance Data, 10 to 500 pg mL⁻¹ (IS 200 pg mL⁻¹).

Matrix	Analyte	Coefficient, <i>r</i>	Accuracy, %	Precision, % RSD	Range, pg mL ⁻¹	Estimated LOQ, pg mL ⁻¹	Estimated LOQ, nmol L ⁻¹
Na heparin	NE	0.9998	90-110	< 10	40-500	22	0.13
	EP	0.9995	80-110	< 10	10-500	8	0.04
	DA	0.9993	90-110	< 10	10-500	4	0.02
	NM	0.9994	90-110	< 10	10-500	3	0.02
	ME	0.9993	90-110	< 10	10-500	2	0.01
	3MT	0.9992	90-120	< 10	10-500	1	0.01
K3EDTA	NE	0.9993	90-110	< 10	40-500	24	0.14
	EP	0.9994	90-110	< 15	10-500	7	0.04
	DA	0.9995	90-110	< 10	10-500	6	0.01
	NM	0.9993	90-110	< 10	10-500	3	0.02
	ME	0.9999	90-110	< 10	10-500	2	0.01
	3MT	0.9997	80-110	< 15	10-500	3	0.02

Table 5. Extrahera™ LV-200 Calibration Performance Data, 10 to 500 pg mL⁻¹ (IS 200 pg mL⁻¹).

Matrix	Analyte	Coefficient, <i>r</i>	Accuracy, %	Precision, % RSD	Range, pg mL ⁻¹	Estimated LOQ, pg mL ⁻¹	Estimated LOQ, nmol L ⁻¹
Na heparin	NE	0.9997	90-110	< 10	40-500	20	0.12
	EP	0.9993	80-110	< 10	10-500	8	0.05
	DA	0.9994	90-110	< 10	10-500	5	0.03
	NM	0.9993	90-110	< 10	10-500	4	0.02
	ME	0.9990	90-120	< 10	10-500	2	0.01
	3MT	0.9985	90-120	< 10	10-500	4	0.02
K3EDTA	NE	0.9994	90-110	< 10	40-500	22	0.13
	EP	0.9990	80-110	< 15	10-500	8	0.04
	DA	0.9979	90-110	< 10	10-500	6	0.04
	NM	0.9991	90-110	< 10	10-500	3	0.02
	ME	0.9991	80-110	< 10	10-500	6	0.03
	3MT	0.9991	80-110	< 15	10-500	2	0.01

Matrix Interferences

The sample preparation procedure described in this application note results in final extracts that are low in matrix interferences, matrix factors are comparable for both manual and automated methods. Matrix factor, determined as the ratio of post extraction spike / dilute standard at the same concentration,

is shown in Figure 5. Signal factor, determined as the ratio of pre-extraction spike / dilute standard, demonstrates matrix has a minimal effect on analyte response used for recovery (with the exception of norepinephrine). Signal factors are comparable for both methods (see Figure 6).




Figure 5. Matrix factors for sodium citrate plasma (PRESSURE+ 96 and Extrahera™ LV-200 methods).




Figure 6. Signal factors for sodium citrate plasma (PRESSURE+96 and Extrahera™ LV-200 methods).

Discussion and Conclusion

The sample preparation method performance data above was generated using an elution solvent with high water content and an evaporation-reconstitution workflow. We recommend this approach to minimize matrix effects. The concentration step ensures this method meets clinically relevant reference intervals without needing a cumbersome derivatization step. Evaporation time is typically 20 minutes for a 100 µL elution volume.

Using a more typical high organic content elution or direct injection of the aqueous elution will improve throughput but may have a detrimental effect on performance, respectively increasing the breakthrough of phospholipids in the final elution or raising achievable limits of quantitation. We used 2% formic acid in 80% MeOH (aq) as an alternative elution solvent, evaporation time was typically 10 minutes. It is possible to directly inject the elution solvent from the method in this application note. However, the injection volume must be reduced to 5 µL so as not to cause peak broadening of early eluting analytes (e.g. norepinephrine).

Inclusion of comprehensive wash and associated drying steps enhances assay robustness, reducing system maintenance at the cost of a small increase in turnaround time. During development of this application, column lifespans were typically over 3000 injections (over 500 hours use).

This method provides high, reproducible recoveries of catecholamines and metanephrines in human plasma treated with typical clinical anticoagulants.

The method described in this application note was automated using a Biotage® Extrahera™ LV-200 system. Total processing time using the Extrahera was approximately 60 minutes for 96 samples (excluding evaporation and transfer steps). Results generated using the automated method demonstrate comparable analyte recovery with lower RSD, indicating improved reproducibility when the process is automated. Matrix and signal factors are comparable between manual and automated methods. Extrahera™ LV-200 linearity and LOQ are comparable to the manual processing method. The appendix contains software settings required to configure an Extrahera™ LV-200 to run the above method.

Additional Information

Chemicals And Reagents

Reagents were purchased from Sigma-Aldrich Company Ltd. (Gillingham UK). LC-MS grade methanol and propan-2-ol (isopropanol) were purchased from Rathburn Chemicals Ltd (Walkerburn UK). Water (18.2 MΩ.cm) was drawn fresh daily from a Milli-Q Direct-Q 5 water purifier (Merck Life Sciences, Gillingham UK).

- » Stock standard diluent: ascorbic acid, 0.04% w/v in methanol. Dilute ascorbic acid (39.5 to 40.5 mg) in methanol (100 ± 0.5 mL). Prepare daily immediately prior to use.
- » Working standard diluent: ascorbic acid, 0.04% w/v in water. Dilute ascorbic acid (39.5 to 40.5 mg) in deionized water (100 ± 0.5 mL). Prepare daily immediately prior to use.
- » Pre-treatment solution: 10 mM sodium citrate pH 7, aq. Dilute trisodium citrate (621 to 625 mg) in deionized water (250 ± 1 mL) and titrate to pH 7.0 using formic acid 10%, aq (approximately 80 µL). Prepare fresh daily.
- » Equilibration and aqueous wash solution: 10 mM ammonium acetate pH 6, aq. Dilute ammonium acetate (383 to 387 mg) in deionized water (500 ± 2 mL) and titrate to pH 6.0 using formic acid 10%, aq (approximately 80 µL). Prepare weekly.
- » Organic wash solution: methanol/water 80:20 v/v. Dilute 20 mL deionized water with 80 mL methanol.
- » Elution solvent: water/propan-2-ol (85:15, v/v) containing formic acid, 0.1% v/v. Dilute 15 mL propan-2-ol with 85 mL deionized water. Further dilute 0.1 mL formic acid in 99.9 mL of water/propan-2-ol (85:15 v/v).
- » Reconstitution solvent: water/methanol (95:5, v/v) containing formic acid (0.1%, v/v). Dilute 5 mL methanol with 95 mL deionized water. Further dilute 0.1 mL formic acid in 99.9 mL of water/methanol (95:5, v/v).
- » Mobile phase A: 2 mM ammonium formate containing formic acid, 0.05% v/v in water. Dilute formic acid (500 ± 1 µL) in deionized water (1000 ± 5 mL). Further dilute ammonium formate (124 to 128 mg) in water containing formic acid, 0.05% v/v (1000 ± 5 mL). Prepare every two days or more frequently if needed.
- » Mobile phase B: 0.5 mM ammonium fluoride in methanol. Dilute ammonium fluoride (9.2 to 9.7 mg) in methanol (500 ± 2 mL), sonicate for 10 to 15 minutes to aid dissolution. Prepared fresh every two days or more frequently if needed.

Standards

Cerilliant® standards were purchased from Sigma-Aldrich Company Ltd. (Gillingham UK) at 1.0 mg mL⁻¹ in methanol. Deuterated Cerilliant® internal standards were purchased from the same at 100 µg mL⁻¹ in methanol.

Extraction Matrices

Gender pooled human plasma was purchased from The Welsh Blood Service (Pontyclun, UK), BioIVT (Burgess Hill, UK), and Golden West Biologicals, Inc. (Temecula, CA). Method linearity and LOQ were determined with plasma prepared using an in-house stripping process. Spike-recovery experiments were performed on unstripped plasma. We recommend plasma is centrifuged for 10 min at 6,000 x g before processing further.

Ordering Information

Part Number	Description	Quantity
602-0002-LVP	Biotage® Mikro WCX 2 mg Plate	1
121-5202	Collection plate, 1 mL Square	50
121-5204	Piercable Sealing Cap	50
Automated processing		
417000	Biotage® Extrahera™ LV-200	1
416920SP	Pipette Rack, LV/MV	1
417423SP	Pipette Rack, Short	1
417008	50 µL Clear Tips	960
417009	200 µL Clear Tips	960
Manual Processing		
PPM-96	Biotage® PRESSURE+ 96 Positive Pressure Manifold (96 position)	1
Evaporation		
SD-9600-DHS-NA	Biotage® SPE Dry Sample Concentrator System 220/240 V	1
SD-9600-DHS-EU	Biotage® SPE Dry Sample Concentrator System 100/120 V	1

Appendix

Biotage® Extrahera™ Settings

The method described in this application note was automated on the Biotage® Extrahera™ LV-200 using Biotage® Mikro WCX plates.

This appendix contains the software settings required to configure Extrahera to run this method. As described in the main body of the application note, analyte recoveries, linearities

and LOQs were comparable for both manually processed and automated methods.

Total time for extraction of 96 samples using this method was approximately 60 minutes (excluding post extraction evaporation and transfer steps).

General tab

Sample type	plasma pretreated 1:1 10 mM sodium citrate pH 7
Sample volume	300 µL

Conditioning tab

Number of steps	1
Pressure (bar)	0.6
Dispose tips	No
Volume (µL)	100
Collect in position	D (W1)
Positive pressure time (s)	50

Advanced pressure settings

None	
-------------	--

Equilibration tab

Method name: AP56 cats WCX Mikro 0.6 bar

Classical plate: 1 ml. Sample Plate, 96

Consumable brand: Biotage Mikro WCX Pla...

Number of steps: 1

Pressure (bar): 0.6

Solvent: 10 mM ammonium acet...

Volume (µL): 100

Positive pressure time (s): 60

Collect in position: D (W1)

Repeat (number of times): 1

Pause after this step: No

Number of steps	1
Pressure (bar)	0.6
Dispose tips	No
Volume (µL)	100
Collect in position	D (W1)
Positive pressure time (s)	60

Advanced pressure settings

None

Load tab

Method name: AP56 cats WCX Mikro 0.6 bar

Classical plate: 1 ml. Sample Plate, 96

Consumable brand: Biotage Mikro WCX Pla...

Sample volume (µL): 200

Pressure (bar): 0.6

Premix?: Yes

Number of times: 1

Positive pressure time (s): 150

Advanced pressure settings: Edit...

Pause after each load?: No

Collect in position: D (W1)

Rinsing?: No

Tip conditioning?: No

Number of steps	1
Pressure (bar)	0.6
Premix (no times)	Yes (1)
Volume (µL)	200
Collect in position	D (W1)
Positive pressure time (s)	150

Advanced pressure settings

None

Wash tab

Number of steps	3
Pressure (bar)	0.6
Plate dry after last wash	Yes
Plate dry time (s)	300

Step 1

Volume (µL)	100
Collect in position	D (W1)
Positive pressure time (s)	80

Advanced pressure settings

None

Step 2

Volume (µL)	100
Collect in position	D (W1)
Positive pressure time (s)	-

Advanced pressure settings

Number of steps	2
Step 2.1 pressure (bar)	0.6
Step 2.1 time (s)	80
Step 2.2 pressure (bar)	5.0
Step 2.2 time (s)	-

Step 3

Volume (µL)	100
Collect in position	B
Positive pressure time (s)	45

Advanced pressure settings

None

Elute tab

Number of steps	1
Pressure (bar)	0.6
Plate dry after last elution	No
Volume (µL)	100
Collect in position	A
Positive pressure time (s)	90

Advanced pressure settings

Number of steps	2
Step 1 pressure (bar)	0.6
Step 1 time (s)	90
Step 2 pressure (bar)	4.0
Step 2 time (s)	10

Literature Number: AN962.v1

© 2021 Biotage. All rights reserved. No material may be reproduced or published without the written permission of Biotage. Information in this document is subject to change without notice and does not represent any commitment from Biotage. E&OE. A list of all trademarks owned by Biotage AB is available at www.biotage.com/legal. Other product and company names mentioned herein may be trademarks or registered trademarks and/or service marks of their respective owners, and are used only for explanation and to the owners' benefit, without intent to infringe.